In contrast to beneficial low-dose IL-2 therapy (2.5 × 104 IU/day), higher IL-2 doses (2.5–5 × 105 IU/day) did not prevent T1D in some mice and even dramatically accelerated onset of diabetes despite local and systemic Treg improvement. Here, IL2 is linked to diabetes mellitus.